argenx NV ADR (ARGX)vsHalozyme Therapeutics Inc (HALO)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
HALO
Halozyme Therapeutics Inc
$71.53
-0.10%
HEALTHCARE · Cap: $8.24B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 214% more annual revenue ($4.74B vs $1.51B). ARGX leads profitability with a 31.4% profit margin vs 23.1%. HALO trades at a lower P/E of 24.4x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
HALO
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for HALO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 159 in profit
Strong operational efficiency at 49.0%
Revenue surging 42.2% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 31.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Grey zone — moderate risk
Weak financial health signals
Trading at 38.7x book value
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : HALO
The strongest argument for HALO centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 49.0%. Revenue growth of 42.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : HALO
The primary concerns for HALO are Altman Z-Score, Piotroski F-Score, Price/Book. Debt-to-equity of 9.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 0.87 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 70/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?